Cargando…

Kinome expression profiling and prognosis of basal breast cancers

BACKGROUND: Basal breast cancers (BCs) represent ~15% of BCs. Although overall poor, prognosis is heterogeneous. Identification of good- versus poor-prognosis patients is difficult or impossible using the standard histoclinical features and the recently defined prognostic gene expression signatures...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sabatier, Renaud, Finetti, Pascal, Mamessier, Emilie, Raynaud, Stéphane, Cervera, Nathalie, Lambaudie, Eric, Jacquemier, Jocelyne, Viens, Patrice, Birnbaum, Daniel, Bertucci, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156788/ https://www.ncbi.nlm.nih.gov/pubmed/21777462 http://dx.doi.org/10.1186/1476-4598-10-86

Ejemplares similares

A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers
por: de Nonneville, Alexandre, et al.
Publicado: (2019)

Prognostic and predictive value of PDL1 expression in breast cancer
por: Sabatier, Renaud, et al.
Publicado: (2014)

A seven-gene prognostic model for platinum-treated ovarian carcinomas
por: Sabatier, R, et al.
Publicado: (2011)

XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma
por: Birnbaum, David Jérémie, et al.
Publicado: (2019)

Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease
por: Mari, Roxane, et al.
Publicado: (2019)

Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization
por: Sabatier, Renaud, et al.
Publicado: (2014)

PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy
por: Bertucci, François, et al.
Publicado: (2015)

Genome profiling of ERBB2-amplified breast cancers
por: Sircoulomb, Fabrice, et al.
Publicado: (2010)

Validation and comparison of the molecular classifications of pancreatic carcinomas
por: Birnbaum, David J., et al.
Publicado: (2017)

Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors
por: Birnbaum, David Jérémie, et al.
Publicado: (2019)

“Stealth” tumors: Breast cancer cells shun NK-cells anti-tumor immunity
por: Mamessier, Emilie, et al.
Publicado: (2012)

Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers
por: Monneur, Audrey, et al.
Publicado: (2017)

Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins?
por: Aulas, Anaïs, et al.
Publicado: (2020)

WEE1 Dependency and Pejorative Prognostic Value in Triple‐Negative Breast Cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2021)

The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer
por: Bertucci, François, et al.
Publicado: (2018)

CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines
por: Zabouo, Gwladys, et al.
Publicado: (2009)

Candidate Luminal B Breast Cancer Genes Identified by Genome, Gene Expression and DNA Methylation Profiling
por: Cornen, Stéphanie, et al.
Publicado: (2014)

High-Resolution Comparative Genomic Hybridization of Inflammatory Breast Cancer and Identification of Candidate Genes
por: Bekhouche, Ismahane, et al.
Publicado: (2011)

Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype
por: de Nonneville, Alexandre, et al.
Publicado: (2023)

Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors
por: Bertucci, François, et al.
Publicado: (2021)

CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
por: Bertucci, François, et al.
Publicado: (2023)

The MonarchE trial: improving the clinical outcome in HR(+)/HER2(−) early breast cancer: recent results and next steps
por: Bertucci, François, et al.
Publicado: (2023)

Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers
por: Letessier, Anne, et al.
Publicado: (2006)

The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtype
por: Bertucci, François, et al.
Publicado: (2020)

Breast Metastasis of a Squamous Cell Carcinoma of the Uterine Cervix Mimicking Inflammatory Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2012)

Are there candidates for high-dose chemotherapy in ovarian carcinoma?
por: Sabatier, Renaud, et al.
Publicado: (2012)

CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
por: Boudin, Laurys, et al.
Publicado: (2022)

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial
por: Jacquemier, Jocelyne, et al.
Publicado: (2011)

Low cholesterol biosynthesis favors epithelial‐to‐mesenchymal transition maintenance and influences tumor molecular subtyping and disease‐free survival in colon cancer patients
por: Aulas, Anaïs, et al.
Publicado: (2022)

CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression
por: Boudin, Laurys, et al.
Publicado: (2022)

Loss, mutation and deregulation of L3MBTL4 in breast cancers
por: Addou-Klouche, Lynda, et al.
Publicado: (2010)

Basal Breast Cancer: A Complex and Deadly Molecular Subtype
por: Bertucci, F, et al.
Publicado: (2012)

MARCKS protein overexpression in inflammatory breast cancer
por: Manai, Maroua, et al.
Publicado: (2016)

Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: Prominent expression of P-cadherin
por: Ben Hamida, Azza, et al.
Publicado: (2008)

Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial
por: Bertucci, François, et al.
Publicado: (2021)

A 25-gene classifier predicts overall survival in resectable pancreatic cancer
por: Birnbaum, David J., et al.
Publicado: (2017)

PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma
por: Birnbaum, David Jeremie, et al.
Publicado: (2023)

Down-Regulation of ECRG4, a Candidate Tumor Suppressor Gene, in Human Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2011)

Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer
por: Guerin, Mathilde, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_equ94rf14kh0bq4smab90iguui